Neogen (NEOG) 10-Q2019 Q1 Quarterly report

Filed: 5 Oct 18, 4:59pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Accumulated, aggregate, aided, amortizable, Asia, assessment, assured, awarded, bad, behavior, beverage, bid, Botulism, breeding, case, charge, charged, chosen, Colitag, Collateral, comparison, complexity, component, conform, contra, conveyed, correct, Corrective, country, coupled, criteria, Department, deposit, derive, derived, disaggregated, discontinuance, doubtful, Eastern, equine, established, European, event, exclusive, exit, expedient, expiration, fourth, fulfillment, genetic, geographic, GILTI, governmental, handle, handling, hierarchy, history, impaired, impairment, incentive, inception, indirectly, individually, infrequent, insignificant, intercompany, invoiced, KY, Lansing, law, Lexington, Livestock, LLC, low, machinery, mandatory, marketplace, met, Michigan, moved, negotiated, NeoKlor, objective, observability, observable, obsolescence, obsolete, ofRegulation, onForm, open, orderly, ourListeria, owner, paper, part, partner, pattern, peer, poor, portfolio, prepaid, preserve, produce, pronouncement, properly, provision, quality, quantitative, quoted, recoverable, regular, remitted, reorder, reperformance, request, retired, SAB, satisfied, security, selected, sell, separately, served, shifted, shipment, short, slightly, software, speculative, statistical, Study, succeeding, system, table, taxation, territorial, title, toForm, treatment, tripled, turn, unchanged, uncollectible, Unobservable, utilize, vaccine, valuation, volatility, warrant, warranty, water, wear, wholly, won

Removed: allergen, allergenic, amendment, approved, biosecurity, calendar, canine, chemical, cleaner, Comercio, companion, contamination, deoxynivalenol, DON, earlier, eliminating, employer, expand, FDA, flat, Formal, formed, fully, grain, implement, Industria, instituted, integrated, land, lost, Ltda, March, marking, milk, moderate, mycotoxin, occur, occurring, outbreak, Paulo, policy, raw, removed, repurchase, repurchased, resulted, Rochdale, rose, Sao, settled, team, thyroid, withholding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated NEOG transcripts

NEOG similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

18 U.S.C. SECTION 1350 CERTIFICATION

NEOGEN CORPORATION

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form10-Q of Neogen Corporation (the “Company”) for the period ended August 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John E. Adent, as Chief Executive Officer of the Company and I, Steven J. Quinlan, as Chief Financial Officer, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

This Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

Information contained in this Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: October 5, 2018

/s/ John E. Adent

John E. Adent

President & Chief Executive Officer

(Principal Executive Officer)

/s/ Steven J. Quinlan

Steven J. Quinlan

Vice President & Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.